Literature DB >> 29985369

Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins.

Meisam Naeimi Kararoudi1, Hamid Dolatshad2, Prashant Trikha1, Syed-Rehan A Hussain3, Ezgi Elmas1, Jennifer A Foltz1, Jena E Moseman1, Aarohi Thakkar1, Robin J Nakkula1, Margaret Lamb1, Nitin Chakravarti1, K John McLaughlin3, Dean A Lee4.   

Abstract

CRISPR/Cas9 technology is accelerating genome engineering in many cell types, but so far, gene delivery and stable gene modification have been challenging in primary NK cells. For example, transgene delivery using lentiviral or retroviral transduction resulted in a limited yield of genetically-engineered NK cells due to substantial procedure-associated NK cell apoptosis. We describe here a DNA-free method for genome editing of human primary and expanded NK cells using Cas9 ribonucleoprotein complexes (Cas9/RNPs). This method allowed efficient knockout of the TGFBR2 and HPRT1 genes in NK cells. RT-PCR data showed a significant decrease in gene expression level, and a cytotoxicity assay of a representative cell product suggested that the RNP-modified NK cells became less sensitive to TGFβ. Genetically modified cells could be expanded post-electroporation by stimulation with irradiated mbIL21-expressing feeder cells.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29985369      PMCID: PMC6101749          DOI: 10.3791/58237

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  19 in total

1.  Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy.

Authors:  Tolga Sutlu; Sanna Nyström; Mari Gilljam; Birgitta Stellan; Steven E Applequist; Evren Alici
Journal:  Hum Gene Ther       Date:  2012-09-10       Impact factor: 5.695

2.  Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles.

Authors:  Ming Wang; John A Zuris; Fantao Meng; Holly Rees; Shuo Sun; Pu Deng; Yong Han; Xue Gao; Dimitra Pouli; Qi Wu; Irene Georgakoudi; David R Liu; Qiaobing Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-29       Impact factor: 11.205

3.  Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra.

Authors:  Juliann Chmielecki; Mark Bailey; Jie He; Julia Elvin; Jo-Anne Vergilio; Shakti Ramkissoon; James Suh; Garrett M Frampton; James X Sun; Samantha Morley; Daniel Spritz; Siraj Ali; Laurie Gay; Rachel L Erlich; Jeffrey S Ross; Joana Buxhaku; Hilary Davies; Vinny Faso; Alexis Germain; Blair Glanville; Vincent A Miller; Philip J Stephens; Katherine A Janeway; John M Maris; Soheil Meshinchi; Trevor J Pugh; Jack F Shern; Doron Lipson
Journal:  Cancer Res       Date:  2017-01-09       Impact factor: 12.701

4.  Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy.

Authors:  Dean A Lee; Michael R Verneris; Dario Campana
Journal:  Methods Mol Biol       Date:  2010

5.  Expansion, purification, and functional assessment of human peripheral blood NK cells.

Authors:  Srinivas S Somanchi; Vladimir V Senyukov; Cecele J Denman; Dean A Lee
Journal:  J Vis Exp       Date:  2011-02-02       Impact factor: 1.355

6.  Genome editing via delivery of Cas9 ribonucleoprotein.

Authors:  Mark A DeWitt; Jacob E Corn; Dana Carroll
Journal:  Methods       Date:  2017-04-12       Impact factor: 3.608

7.  TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway.

Authors:  Sébastien Viel; Antoine Marçais; Fernando Souza-Fonseca Guimaraes; Roisin Loftus; Jessica Rabilloud; Morgan Grau; Sophie Degouve; Sophia Djebali; Amélien Sanlaville; Emily Charrier; Jacques Bienvenu; Julien C Marie; Christophe Caux; Jacqueline Marvel; Liam Town; Nicholas D Huntington; Laurent Bartholin; David Finlay; Mark J Smyth; Thierry Walzer
Journal:  Sci Signal       Date:  2016-02-16       Impact factor: 8.192

8.  Retroviral gene transfer into primary human natural killer cells.

Authors:  Evren Alici; Tolga Sutlu; M Sirac Dilber
Journal:  Methods Mol Biol       Date:  2009

9.  Efficient DNA-free genome editing of bread wheat using CRISPR/Cas9 ribonucleoprotein complexes.

Authors:  Zhen Liang; Kunling Chen; Tingdong Li; Yi Zhang; Yanpeng Wang; Qian Zhao; Jinxing Liu; Huawei Zhang; Cuimin Liu; Yidong Ran; Caixia Gao
Journal:  Nat Commun       Date:  2017-01-18       Impact factor: 14.919

Review 10.  Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.

Authors:  Rohtesh S Mehta; Katayoun Rezvani
Journal:  Front Immunol       Date:  2018-02-15       Impact factor: 7.561

View more
  19 in total

1.  CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity.

Authors:  Meisam Naeimi Kararoudi; Yuya Nagai; Ezgi Elmas; Marcelo de Souza Fernandes Pereira; Syed Abbas Ali; Philip Hollingsworth Imus; Darren Wethington; Ivan Marques Borrello; Dean Anthony Lee; Gabriel Ghiaur
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

Review 2.  Cellular pathways in the development of human and murine innate lymphoid cells.

Authors:  Steven D Scoville; Aharon G Freud; Michael A Caligiuri
Journal:  Curr Opin Immunol       Date:  2018-12-19       Impact factor: 7.486

3.  Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy.

Authors:  Aaron J Wilk; Nancy Lynn-Benner Weidenbacher; Rosemary Vergara; Ole A W Haabeth; Ronald Levy; Robert M Waymouth; Paul A Wender; Catherine A Blish
Journal:  Blood Adv       Date:  2020-09-08

Review 4.  Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9.

Authors:  Lukman O Afolabi; Adeleye O Adeshakin; Musbahu M Sani; Jiacheng Bi; Xiaochun Wan
Journal:  Immunology       Date:  2019-08-14       Impact factor: 7.397

5.  Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity.

Authors:  Meisam Naeimi Kararoudi; Brian P Tullius; Nitin Chakravarti; Emily J Pomeroy; Branden S Moriarity; Kathie Beland; Aurelien B L Colamartino; Elie Haddad; Yaya Chu; Mitchell S Cairo; Dean A Lee
Journal:  Semin Hematol       Date:  2020-11-19       Impact factor: 3.851

6.  Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV.

Authors:  Meisam Naeimi Kararoudi; Shibi Likhite; Ezgi Elmas; Kenta Yamamoto; Maura Schwartz; Kinnari Sorathia; Marcelo de Souza Fernandes Pereira; Yasemin Sezgin; Raymond D Devine; Justin M Lyberger; Gregory K Behbehani; Nitin Chakravarti; Branden S Moriarity; Kathrin Meyer; Dean A Lee
Journal:  Cell Rep Methods       Date:  2022-06-13

Review 7.  NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.

Authors:  Carlos E Sanchez; Ehsan P Dowlati; Ashley E Geiger; Kajal Chaudhry; Matthew A Tovar; Catherine M Bollard; Conrad Russell Y Cruz
Journal:  Transplant Cell Ther       Date:  2020-09-29

Review 8.  Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy.

Authors:  Rasa Islam; Aleta Pupovac; Vera Evtimov; Nicholas Boyd; Runzhe Shu; Richard Boyd; Alan Trounson
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

Review 9.  Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer.

Authors:  Samantha M Fix; Amir A Jazaeri; Patrick Hwu
Journal:  Cancer Discov       Date:  2021-02-09       Impact factor: 39.397

Review 10.  Nonviral genome engineering of natural killer cells.

Authors:  Gabrielle M Robbins; Minjing Wang; Emily J Pomeroy; Branden S Moriarity
Journal:  Stem Cell Res Ther       Date:  2021-06-16       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.